Business
USANA Health Sciences sells nutritional and personal-care products through direct selling.
USANA Health Sciences grew revenue, remained profitable, generated positive free cash flow at a 4.0% operating margin. Profit and free cash flow were thin, while inventory and capital spending outgrew revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 8.3%OK
- Profitability — Net income declined 74.4% to $10.76M from $42.03MWatch
- Cash flow — Free cash flow declined 83.3% to $8.526M from $50.919MWatch
- Margins — Operating margin contracted 371 bps to 4.05%Watch
- Accounting — Profit and free cash flow were thin, while inventory and capital spending outgrew revenueNote
- Insiders — 0 purchases and 19 salesWatch
Where the revenue comes from
Fiscal 2025, as USANA HEALTH SCIENCES INC reports it. History and quarterly detail are in the app.
- Core nutritional$775.5M
- Hiya direct-to-consumer$132.0M
- Other$17.8M
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-05-20
- 10-Q · Quarterly report2026-05-12
- 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about USANA HEALTH SCIENCES INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.